Search Results
Found 2 results
510(k) Data Aggregation
(60 days)
QUICKTOX MULTIPLE DRUG DIPCARD
The QuickTox™ Multiple Drug Dipcard is an in vitro screen test that contains chromatographic immunoassays for the rapid detection of cocaine (benzoylecgonine). morphine, methamphetamine, THC, amphetamines, phencyclidine, benzodiazepine (oxazepam), barbiturate (secobarbital), methadone, nortriptyline and their metabolites in human urine. The cutoff concentrations are as follow:
| COC | Benzoylecgonine | 300 ng/ml |
|---|---|---|
| MOR2000 | Morphine 2000 | 2000 ng/ml |
| MOR300 | Morphine 300 | 300 ng/ml |
| MET1000 | Methamphetamine 1000 | 1000 ng/ml |
| MET500 | Methamphetamine 500 | 500 ng/ml |
| THC | 11-nor- Delta 9 -Tetrahydrocannabinol-9-carboxylic acid | 50 ng/ml |
| AMP | Amphetamine | 1000 ng/ml |
| PCP | Phencyclidine | 25 ng/ml |
| BZO | Oxazepam | 300 ng/ml |
| BAR | Secobarbital | 300 ng/ml |
| MTD | Methadone | 300 ng/ml |
| TCA | Nortriptyline | 1000 ng/ml |
The QuickTox™ Multiple Drug Dipcard is used to obtain visual, qualitative results for multiple drugs-of-abused in humane urine. The device is intended for professional in vitro diagnostic use only. It is not intended for over-the-counter sale to lay persons.
Not Found
This document is a 510(k) premarket notification from the FDA for a diagnostic device, not a study report. Therefore, it does not contain the detailed information about acceptance criteria or a study that proves the device meets those criteria in the typical format of a clinical trial or algorithm validation study.
However, based on the provided text, we can infer some aspects and extract what information is present, and explicitly state what is missing.
Here's an analysis based on your request, focusing on the available information:
Device Name: QuickTox™ Multiple Drug Dipcard - COC/MOR/MET/THC/AMP/PCP/BZO/BAR/MTD/TCA
Indications For Use: The QuickTox™ Multiple Drug Dipcard is an in vitro screen test that contains chromatographic immunoassays for the rapid detection of cocaine (benzoylecgonine), morphine, methamphetamine, THC, amphetamines, phencyclidine, benzodiazepine (oxazepam), barbiturate (secobarbital), methadone, nortriptyline and their metabolites in human urine. The device is intended for professional in vitro diagnostic use only. It is not intended for over-the-counter sale to lay persons.
1. A table of acceptance criteria and the reported device performance
The provided document lists "cutoff concentrations" for each drug, which serve as the analytical acceptance criteria for detecting the presence of that drug. The document does not provide specific reported device performance metrics (like sensitivity, specificity, accuracy, positive predictive value, negative predictive value) against a gold standard for these cutoffs in a study. It only states the intended cutoffs.
| Drug / Metabolite | Cutoff Concentration (Acceptance Criteria) | Reported Device Performance |
|---|---|---|
| COC (Benzoylecgonine) | 300 ng/ml | Not Reported in document |
| MOR2000 (Morphine 2000) | 2000 ng/ml | Not Reported in document |
| MOR300 (Morphine 300) | 300 ng/ml | Not Reported in document |
| MET1000 (Methamphetamine 1000) | 1000 ng/ml | Not Reported in document |
| MET500 (Methamphetamine 500) | 500 ng/ml | Not Reported in document |
| THC (11-nor-$\Delta^9$-Tetrahydrocannabinol-9-carboxylic acid) | 50 ng/ml | Not Reported in document |
| AMP (Amphetamine) | 1000 ng/ml | Not Reported in document |
| PCP (Phencyclidine) | 25 ng/ml | Not Reported in document |
| BZO (Oxazepam) | 300 ng/ml | Not Reported in document |
| BAR (Secobarbital) | 300 ng/ml | Not Reported in document |
| MTD (Methadone) | 300 ng/ml | Not Reported in document |
| TCA (Nortriptyline) | 1000 ng/ml | Not Reported in document |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
This information is not provided in the document. The document is a regulatory clearance letter, not a study report.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
This information is not provided in the document. For drug tests, ground truth is typically established by more definitive analytical methods (e.g., GC/MS), not by expert human readers.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This information is not provided in the document. Adjudication methods are typically relevant for subjective interpretations (e.g., imaging studies), whereas this device provides visual, qualitative results based on a chemical reaction.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
An MRMC study is not applicable and was not done as described in the document. This device is an in vitro diagnostic test (a chemical assay), not an AI-assisted diagnostic tool that human readers would interpret. The document refers to "visual, qualitative results for multiple drugs-of-abused in human urine" which implies a direct observation of a color change or line on the dipcard, not interpretation by human readers in the context of an MRMC study.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This device itself is a standalone test, but it is not an "algorithm" in the typical sense of a software-based AI system. It's a chemical immunoassay. The device provides "visual, qualitative results," meaning a human visually interprets the presence or absence of lines on the dipcard. So, while it's a standalone test, it's not "algorithm-only" and does involve human visual interpretation. The document does not describe a study to evaluate this "standalone" performance against a gold standard.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The document does not explicitly state the type of ground truth used for any validation study. For drug screening tests, the ground truth is typically established by a confirmatory analytical method, such as Gas Chromatography-Mass Spectrometry (GC/MS) or Liquid Chromatography-Mass Spectrometry (LC/MS), which provides highly accurate and quantitative measurements of drug concentrations in urine samples.
8. The sample size for the training set
This information is not provided in the document. As an in vitro diagnostic immunoassay, it doesn't typically have a "training set" in the machine learning sense. Its development involves chemical formulation and optimization.
9. How the ground truth for the training set was established
This information is not provided in the document, as the concept of a "training set" with established ground truth is not explicitly mentioned or applicable in the AI/machine learning context for this type of device based on the provided text. The development of such a device involves analytical validation, likely using spiked samples and clinical samples confirmed by reference methods.
Ask a specific question about this device
(11 days)
QUICKTOX MULTIPLE DRUG DIPCARD COC/MET/THC/AMP/PCP/BZO/BAR/MTD/TCA, MODEL QT61
The QuickTox™ Multiple Drug Dipcard is an in vitro screen test that contains chromatographic immunoassays for the rapid detection of cocaine (benzoylecgonine), morphine, methamphetamine, THC, amphetamines, phencyclidine, benzodiazepine (oxazepam), barbiturate (secobarbital), methadone, nortriptyline and their metabolites in human urine. The cutoff concentrations are as follow:
| COC | Benzoylecgonine | 300 ng/ml |
|---|---|---|
| MOR | Morphine | 2000 ng/ml |
| MET | Methamphetamine | 1000 ng/ml |
| THC | 11-nor- $$\Delta^9$$ -Tetrahydrocannabinol-9-carboxylic acid | 50 ng/ml |
| AMP | Amphetamine | 1000 ng/ml |
| PCP | Phencyclidine | 25 ng/ml |
| BZO | Oxazepam | 300 ng/ml |
| BAR | Secobarbital | 300 ng/ml |
| MTD | Methadone | 300 ng/ml |
| TCA | Nortriptyline | 1000 ng/ml |
The QuickTox™ Multiple Drug Dipcard is used to obtain visual, qualitative results for multiple drugs-of-abused in humane urine. The device is intended for professional in vitro diagnostic use only. It is not intended for over-the-counter sale to lay persons.
The QuickTox™ Multiple Drug Dipcard is an in vitro screen test that contains chromatographic immunoassays for the rapid detection of cocaine (benzoylecgonine), morphine, methamphetamine, THC, amphetamines, phencyclidine, benzodiazepine (oxazepam), barbiturate (secobarbital), methadone, nortriptyline and their metabolites in human urine.
The provided document is a 510(k) clearance letter for the QuickTox™ Multiple Drug Dipcard. It describes the device's intended use and the cutoff concentrations for various drugs, but it does not contain a study or data proving the device meets specific acceptance criteria.
Therefore, I cannot fulfill your request for:
- A table of acceptance criteria and the reported device performance: This information is not present in the document.
- Sample size used for the test set and the data provenance: Not provided.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not provided.
- Adjudication method: Not provided.
- Multi-reader multi-case (MRMC) comparative effectiveness study: Not provided.
- Standalone (i.e. algorithm only without human-in-the loop performance) study: Not applicable as this is a physical diagnostic device, not an AI algorithm.
- Type of ground truth used: Not provided.
- Sample size for the training set: Not applicable as this is a physical diagnostic device, not an AI algorithm.
- How the ground truth for the training set was established: Not applicable as this is a physical diagnostic device, not an AI algorithm.
What the document does provide:
The document primarily serves as an FDA clearance letter, indicating that the device has been found substantially equivalent to a legally marketed predicate device. It specifies:
- Trade/Device Name: QuickTox™ Multiple Drug Dipcard-COC/MOR/MET/THC/AMP/PCP/BZO/BAR/MTD/TCA
- Regulation Number and Name: 21 CFR 862.3250, Cocaine and cocaine metabolite test system (and other product codes for the other drugs)
- Regulatory Class: Class II
- Indications For Use: An in vitro screen test that contains chromatographic immunoassays for the rapid detection of cocaine (benzoylecgonine), morphine, methamphetamine, THC, amphetamines, phencyclidine, benzodiazepine (oxazepam), barbiturate (secobarbital), methadone, nortriptyline and their metabolites in human urine.
- Cutoff Concentrations (which could be considered part of the "acceptance criteria" for qualitative detection thresholds):
| Drug | Metabolite/Compound Assessed | Cutoff Concentration |
|---|---|---|
| COC | Benzoylecgonine | 300 ng/ml |
| MOR | Morphine | 2000 ng/ml |
| MET | Methamphetamine | 1000 ng/ml |
| THC | 11-nor-$\Delta^9$-Tetrahydrocannabinol-9-carboxylic acid | 50 ng/ml |
| AMP | Amphetamine | 1000 ng/ml |
| PCP | Phencyclidine | 25 ng/ml |
| BZO | Oxazepam | 300 ng/ml |
| BAR | Secobarbital | 300 ng/ml |
| MTD | Methadone | 300 ng/ml |
| TCA | Nortriptyline | 1000 ng/ml |
- Intended Use Details: Used to obtain visual, qualitative results for multiple drugs-of-abuse in human urine. Intended for professional in vitro diagnostic use only, not for over-the-counter sale.
To obtain the detailed study information you requested (like sample sizes, ground truth establishment, performance metrics beyond cutoffs), one would typically need to review the original 510(k) submission summary or associated scientific literature, which is not provided in this document. The FDA clearance letter summarizes the regulatory decision, but not the underlying technical validation studies in detail.
Ask a specific question about this device
Page 1 of 1